Neuronetics, Inc. STIM
- Market cap
- $214.9M
- P/E
- 0.0×
Follow STIM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 15.40 | 3.96 | 1.25 | 3.75 | 1.98 | 1.03 | 0.52 | 1.25 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | 39.39 | 19.85 | 11.71 | 22.43 | 6.92 | 6.95 | 5.07 | 5.92 |
High Price
|
|||
| — | 167 | 133 | 235 | 126 | 175 | 194 | 203 | 716 | 658 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 34 | 40 | 53 | 63 | 49 | 55 | 65 | 71 | 75 | 149 |
Revenue
|
|||
| 80.65% | 76.18% | 76.42% | 75.44% | 76.54% | 78.93% | 76.26% | 72.47% | 72.32% | 48.48% |
Gross Margin
|
|||
| (11) | (16) | (24) | (29) | (27) | (31) | (37) | (30) | (44) | (39) |
EBT
|
|||
| (32.82%) | (39.72%) | (45.66%) | (46.35%) | (55.75%) | (56.39%) | (56.99%) | (42.31%) | (58.39%) | (26.24%) |
EBT Margin
|
|||
| (11) | (16) | (24) | (29) | (27) | (31) | (37) | (30) | (44) | (39) |
Net Income
|
|||
| 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 |
Depreciation
|
|||
| 234.44 | 217.38 | 5.90 | 3.41 | 2.61 | 2.17 | 2.42 | 2.49 | 2.36 | 2.26 |
Revenue/Sh
|
|||
| (76.95) | (86.34) | (2.69) | (1.58) | (1.46) | (1.22) | (1.38) | (1.05) | (1.37) | (0.59) |
Earnings/Sh
|
|||
| (58.50) | (59.91) | (2.30) | (1.66) | (1.51) | (1.10) | (1.14) | (1.12) | (0.98) | (0.31) |
Cash Flow/Sh
|
|||
| (2.22) | (3.19) | (0.11) | (0.04) | (0.04) | (0.09) | (0.12) | (0.08) | (0.05) | (0.01) |
Capex/Sh
|
|||
| (60.72) | (63.11) | (2.41) | (1.70) | (1.55) | (1.19) | (1.26) | (1.20) | (1.02) | (0.32) |
Free CF/Sh
|
|||
| (32.97) | (29.66) | 7.94 | 2.60 | 1.35 | 3.34 | 2.12 | 1.19 | 1.00 | 0.40 |
Book Value/Sh
|
|||
| 0 | 0 | 9 | 18 | 19 | 25 | 27 | 29 | 32 | 66 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.00 | 0.00 | 3.28 | 1.32 | 4.25 | 2.05 | 2.72 | 1.10 | 0.68 | 0.61 |
PS Ratio
|
|||
| 0.00 | 0.00 | 2.44 | 1.72 | 8.21 | 1.33 | 3.11 | 2.31 | 1.61 | 3.47 |
PB Ratio
|
|||
| 0.00 | 0.00 | 1.97 | 0.59 | 3.93 | 0.96 | 2.17 | 1.10 | 1.34 | 0.91 |
EV/Sales
|
|||
| (0.19) | (0.19) | (4.81) | (1.19) | (6.65) | (1.76) | (4.16) | (2.28) | (3.09) | (6.43) |
EV/FCF
|
|||
| (9) | (11) | (21) | (30) | (28) | (28) | (31) | (32) | (31) | (20) |
Op' Cash Flow
|
|||
| 0 | (1) | (1) | (1) | (1) | (2) | (3) | (2) | (1) | (1) |
Capex
|
|||
| (9) | (12) | (22) | (31) | (29) | (30) | (34) | (34) | (32) | (21) |
FCF
|
|||
| 10 | 25 | 101 | 61 | 51 | 100 | 66 | 74 | 27 | 31 |
Working Cap'
|
|||
| 20 | 30 | 30 | 31 | 35 | 36 | 36 | 59 | 55 | 66 |
Total Debt
|
|||
| 3 | 0 | (74) | (45) | (16) | (60) | (36) | (1) | 35 | 31 |
Net Debt
|
|||
| (5) | (6) | 71 | 48 | 25 | 85 | 57 | 34 | 32 | 26 |
Sh' Equity
|
|||
| (35.25%) | (50.39%) | (30.90%) | (26.75%) | (30.70%) | (28.37%) | (28.79%) | (25.95%) | (34.05%) | (27.61%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | (697.81%) | (141.37%) | (69.35%) | (103.82%) | (58.06%) | (32.11%) | (34.06%) |
ROIC
|
|||
| 6.08% | 8.69% | 39.63% | (48.86%) | (74.86%) | (56.37%) | (52.25%) | (66.17%) | (132.47%) | (134.39%) |
ROE
|
|||
Neuronetics, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PROF Profound Medical | $204.6M | 0.0× | Compare |
| ELMD Electromed, Inc. | $233.1M | 20.4× | Compare |
| RXST RxSight, Inc. | $196.7M | 0.0× | Compare |
| INFU InfuSystems Holdings, Inc. | $252.8M | 30.3× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QSI Quantum-Si Incorporated | $172.9M | 0.0× | Compare |
| LUCD Lucid Diagnostics Inc. | $170.3M | 0.0× | Compare |
| CATX Perspective Therapeutics, Inc. | $285.4M | 0.0× | Compare |
| RCEL Avita Medical Inc. | $289.1M | 0.0× | Compare |
Neuronetics, Inc. (STIM) key facts
- Neuronetics, Inc. (STIM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- As of September 25, 2026, STIM traded at $2.74, a market capitalization of $214.9 million.
- Return on equity was −134.4% and debt-to-equity 2.84.
Neuronetics, Inc. (STIM) Latest News
8 Sep
Neuronetics launches first-ever TMS integration with EHR/EMR systems through NeuroStar to advance practice innovation. First-ever TMS-EHR/EMR integration delivers major competitive edge and adoption potential for Neuronetics.
18 Aug
Neuronetics (STIM) released its Q2 2026 earnings call transcript covering financial results, operational updates, and management commentary on performance and outlook. Earnings call transcripts deliver detailed financial results and forward guidance that typically drive notable shifts in investor sentiment and stock trajectory.
11 Aug
Neuronetics Inc (STIM) reported revenue growth and margin expansion during its Q2 2026 earnings call. Revenue growth and margin expansion signal stronger financial results that can drive notable gains in stock valuation and investor outlook.
Neuronetics held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance for STIM. Quarterly earnings and guidance typically influence near-term sentiment and valuation without shifting long-term fundamentals.
Neuronetics held its Q2 earnings call and shared updates on financial results, operations, and outlook. Q2 earnings call reveals performance details that can moderately shift investor sentiment and near-term stock movement.
Neuronetics narrowed its Q2 loss while revenue rose 9 percent driven by Greenbrook growth. Quarterly revenue growth and narrowed loss reflect routine financial improvement without major strategic or market shifts.
Neuronetics, Inc. (STIM) released its second quarter 2026 financial and operating results. Quarterly financial results directly influence investor views on performance and near-term outlook.
28 Jul
Greenbrook opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland. New center expands potential use of Neuronetics TMS therapies through additional treatment capacity.
14 May
Neuronetics and ANT Neuro announce strategic collaboration to integrate neuronavigation technology with NeuroStar TMS treatment, enhancing precision for TMS therapy delivery. Integration of neuronavigation boosts NeuroStar TMS precision and therapeutic outcomes, enabling stronger competitive positioning and potential revenue growth.
5 May
Neuronetics, Inc. (STIM) released Q1 earnings call highlights covering financial results, operational updates, and future outlook. Q1 earnings call highlights detail financial performance and guidance, likely driving significant shifts in investor sentiment and market trajectory.
Neuronetics (STIM) released Q1 2026 earnings call transcript detailing financial results, operational updates, and management's outlook. Q1 2026 earnings transcript reveals financial performance and strategic guidance directly influencing STIM's trajectory and investor sentiment.
Neuronetics, Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Quarterly earnings summaries provide insights into financial performance and guidance that moderately influence market sentiment and trajectory.
Neuronetics (STIM) reported a Q1 net loss but exceeded revenue estimates. Beating revenue estimates despite Q1 loss provides moderate boost to financial outlook and market sentiment.
Neuronetics, Inc. (STIM) reported first quarter 2026 financial and operating results. Quarterly earnings reports moderately influence financial performance and investor sentiment for Neuronetics.
2 May
Neuronetics (STIM) investment story evolves with analysts resetting price target amid ongoing developments. Reset price target amid evolving investment story signals major shift in valuation expectations and investor sentiment.
18 Apr
Analysts rework valuation assumptions for Neuronetics (STIM), resetting the investment story amid evolving market perspectives. Analysts reworking valuations resets Neuronetics' investment narrative, likely significantly altering investor sentiment and stock trajectory.
13 Apr
Optum/United Healthcare/United Behavioral Health expands NeuroStar® TMS coverage to include Psychiatric Mental Health Nurse Practitioners, increasing access to Neuronetics' transcranial magnetic stimulation therapy for depression treatment. Coverage expansion by major insurers to nurse practitioners boosts patient access and utilization of NeuroStar TMS, significantly enhancing Neuronetics' revenue potential and market position.
7 Apr
Neuronetics, Inc. (STIM) issued a statement responding to a letter from Pointillist Family Office, likely addressing investor concerns or activist proposals regarding company strategy or governance. Response to activist investor letter from Pointillist Family Office may influence shareholder sentiment, governance discussions, and short-term market performance.
6 Apr
Jorey Chernett, Neuronetics Inc. (STIM)'s largest independent shareholder, demands an immediate and comprehensive review of strategic alternatives, including sale of the TMS business. Major shareholder's call for strategic review including potential sale of core TMS business signals significant shifts in company direction and investor sentiment.
3 Apr
Analysts are revising valuation assumptions for Neuronetics (STIM), shifting the company's investment narrative amid changing fundamentals. Analyst revisions to valuation assumptions will moderately influence STIM's investor sentiment and stock trajectory.
17 Mar
Neuronetics, Inc. (STIM) released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings results and guidance significantly shape investor expectations and stock trajectory.
Neuronetics (STIM) released Q4 2025 earnings call transcript detailing financial results, operational updates, and forward guidance. Q4 earnings transcripts disclose key financial metrics, guidance, and strategic insights that significantly shape investor sentiment and company trajectory.
Neuronetics, Inc. (STIM) reported fourth quarter and full-year 2025 financial and operating results. Full-year financial results disclosure drives substantial shifts in investor sentiment and stock valuation.
Neuronetics, Inc. (STIM) appoints Dan Reuvers as President and Chief Executive Officer. Appointing a new President and CEO signals a major leadership transition with potential to reshape strategic direction and investor sentiment.
Neuronetics Q4 earnings call highlights financial results, operational updates, NeuroStar performance, and 2024 guidance amid revenue growth and strategic initiatives. Q4 earnings highlights detail financial performance and forward guidance with moderate influence on investor sentiment and trajectory.
Neuronetics Inc. (STIM) released Q4 earnings snapshot showing revenue of $11.1 million, down 6% year-over-year, net loss of $9.2 million or $0.36 per share, with full-year revenue at $45.4 million and narrowed net loss. Q4 earnings highlight financial performance and operational trends with moderate influence on investor sentiment and short-term stock trajectory.
13 Feb
Neuronetics, Inc. reported positive cash flow and strong preliminary revenue for Q4, indicating a potential turnaround in financial performance. The company is expected to benefit from increased demand for its neurostimulation devices, which may enhance its market position and investor confidence. Analysts are optimistic about the implications of these results on future growth and profitability. Strong preliminary revenue and positive cash flow suggest significant improvements in financial performance and market positioning.
11 Feb
Neuronetics, Inc. (STIM) has been identified as one of the top midday gainers in the stock market, reflecting a positive shift in investor sentiment and potential interest in the company's offerings. This uptick in stock performance may indicate growing confidence in Neuronetics' business strategies and market position. The stock's midday gain suggests a moderately noticeable influence on market sentiment and potential financial performance.
10 Feb
Neuronetics, Inc. (STIM) has announced selected preliminary unaudited financial results for the fourth quarter and full year of 2025, indicating a positive trend in revenue growth and operational performance. The company highlights increased demand for its NeuroStar Advanced Therapy System, which is expected to drive future growth. Management expresses optimism about the upcoming year, citing strategic initiatives aimed at expanding market reach and enhancing product offerings. The announcement of preliminary financial results and growth in demand for key products suggests significant potential for future performance and market positioning.
12 Nov
TRICARE West has expanded coverage for NeuroStar® TMS therapy to include adolescents aged 15 and older who are struggling with depression. This decision aims to provide more treatment options for younger patients and reflects a growing recognition of the need for mental health support in this age group. NeuroStar® TMS therapy is a non-invasive treatment that has been effective for adults, and its inclusion in TRICARE's coverage for adolescents is expected to enhance access to care for this demographic. The expansion of coverage for adolescents significantly broadens the potential market for NeuroStar® TMS therapy, likely enhancing revenue opportunities for Neuronetics, Inc.